Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above Fifty Day Moving Average – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $13.56 and traded as high as $14.55. Astellas Pharma shares last traded at $14.11, with a volume of 118,178 shares.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALPMY. Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Citigroup cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Astellas Pharma presently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. The stock has a 50 day simple moving average of $13.56 and a 200 day simple moving average of $11.95.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).